Antitrust Antitrust

Chinese drugmaker Puyunhui questions SAMR's inconsistency in penalty decision at court

By Yonnex Li
  • 17 Dec 2020 01:02
  • 17 Dec 2020 03:09
Weifang Puyunhui Pharmaceutical, a Chinese supplier of raw materials for pharmaceutical products, has argued at a Beijing court that the country's competition regulator showed inconsistency in its penalty decision against the company and two other industry peers regarding allegations they collectively abused their market dominance.

The State Administration for Market Regulation, or SAMR,

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Discover MLex

Stay on top of global regulatory developments


Latest News